Gary Nachman
Stock Analyst at Raymond James
(2.79)
# 1,764
Out of 4,784 analysts
101
Total ratings
60.87%
Success rate
0.37%
Average return
Main Sectors:
Stocks Rated by Gary Nachman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Reiterates: Outperform | $218 → $220 | $205.29 | +7.17% | 14 | Feb 3, 2025 | |
| SDGR Schrödinger | Maintains: Outperform | $25 → $28 | $19.96 | +40.28% | 5 | Nov 13, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $275 → $298 | $268.46 | +11.00% | 7 | Nov 1, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | $37 | $25.64 | +44.31% | 1 | Sep 27, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Strong Buy | $20 | $2.78 | +619.42% | 1 | Sep 27, 2024 | |
| PCRX Pacira BioSciences | Maintains: Outperform | $41 → $37 | $24.91 | +48.53% | 13 | Jul 31, 2024 | |
| BLCO Bausch + Lomb | Initiates: Outperform | $19 | $14.13 | +34.47% | 1 | Jul 10, 2024 | |
| AMGN Amgen | Reinstates: Market Perform | n/a | $306.95 | - | 1 | Mar 28, 2024 | |
| SRRK Scholar Rock Holding | Initiates: Strong Buy | $30 | $32.84 | -8.65% | 5 | Mar 28, 2024 | |
| AQST Aquestive Therapeutics | Initiates: Outperform | $7 | $3.02 | +131.79% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $3 | $0.51 | +490.43% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $122.92 | - | 11 | Sep 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $4 | $8.28 | -51.69% | 5 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $6.60 | +354.55% | 4 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $67 | $31.15 | +115.09% | 2 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $32 | $2.31 | +1,285.28% | 1 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $16 → $14 | $8.68 | +61.29% | 2 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $75 | $9.15 | +719.67% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $43 → $40 | $8.28 | +383.09% | 8 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $11 → $10 | $15.08 | -33.69% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $17.88 | +67.79% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $810 → $750 | $2.74 | +27,272.26% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $8 | $6.48 | +23.46% | 2 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $21 | $28.43 | -26.13% | 5 | May 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $14 | $2.78 | +404.50% | 2 | Jun 14, 2018 |
AbbVie
Feb 3, 2025
Reiterates: Outperform
Price Target: $218 → $220
Current: $205.29
Upside: +7.17%
Schrödinger
Nov 13, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $19.96
Upside: +40.28%
Alnylam Pharmaceuticals
Nov 1, 2024
Maintains: Outperform
Price Target: $275 → $298
Current: $268.46
Upside: +11.00%
LENZ Therapeutics
Sep 27, 2024
Initiates: Outperform
Price Target: $37
Current: $25.64
Upside: +44.31%
Achieve Life Sciences
Sep 27, 2024
Initiates: Strong Buy
Price Target: $20
Current: $2.78
Upside: +619.42%
Pacira BioSciences
Jul 31, 2024
Maintains: Outperform
Price Target: $41 → $37
Current: $24.91
Upside: +48.53%
Bausch + Lomb
Jul 10, 2024
Initiates: Outperform
Price Target: $19
Current: $14.13
Upside: +34.47%
Amgen
Mar 28, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $306.95
Upside: -
Scholar Rock Holding
Mar 28, 2024
Initiates: Strong Buy
Price Target: $30
Current: $32.84
Upside: -8.65%
Aquestive Therapeutics
Mar 28, 2024
Initiates: Outperform
Price Target: $7
Current: $3.02
Upside: +131.79%
Mar 28, 2024
Initiates: Outperform
Price Target: $3
Current: $0.51
Upside: +490.43%
Sep 29, 2023
Initiates: Market Perform
Price Target: n/a
Current: $122.92
Upside: -
Mar 3, 2023
Maintains: Market Perform
Price Target: $5 → $4
Current: $8.28
Upside: -51.69%
Mar 1, 2023
Maintains: Outperform
Price Target: $35 → $30
Current: $6.60
Upside: +354.55%
Feb 23, 2023
Maintains: Outperform
Price Target: $70 → $67
Current: $31.15
Upside: +115.09%
Feb 22, 2023
Maintains: Outperform
Price Target: $40 → $32
Current: $2.31
Upside: +1,285.28%
Feb 17, 2023
Downgrades: Market Perform
Price Target: $16 → $14
Current: $8.68
Upside: +61.29%
Nov 14, 2022
Maintains: Outperform
Price Target: $90 → $75
Current: $9.15
Upside: +719.67%
Nov 9, 2022
Maintains: Market Perform
Price Target: $43 → $40
Current: $8.28
Upside: +383.09%
Nov 7, 2022
Maintains: Market Perform
Price Target: $11 → $10
Current: $15.08
Upside: -33.69%
Nov 4, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $17.88
Upside: +67.79%
Aug 11, 2022
Maintains: Outperform
Price Target: $810 → $750
Current: $2.74
Upside: +27,272.26%
Aug 10, 2022
Maintains: Market Perform
Price Target: $15 → $8
Current: $6.48
Upside: +23.46%
May 11, 2020
Maintains: Market Perform
Price Target: $20 → $21
Current: $28.43
Upside: -26.13%
Jun 14, 2018
Maintains: Outperform
Price Target: $24 → $14
Current: $2.78
Upside: +404.50%